On Saturday, Boston Scientific Corporation BSX unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device.
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO ,
Boston Scientific Corporation (NYSE:BSX ) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Jonathan Monson - Senior Vice President, Investor Relations Nick Spadea-An
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company
Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Kidney Stone Management Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global market size for kidn
MARLBOROUGH, Mass. , Nov. 5, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024.
Acquisition to complement electrophysiology portfolio with solution to advance the treatment of complex atrial fibrillation MARLBOROUGH, Mass. , Nov. 4, 2024 /PRNewswire/ -- Boston Scientific Corporat
Boston Scientific Corporation (NYSE:BSX ) Business Update Earnings Conference Call October 30, 2024 4:00 PM ET Company Participants Jonathan Monson - Senior Vice President of Investor Relations Joseph
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific are included in this Analyst Blog.
Medical devices maker Boston Scientific should continue to grow profitably through the next several years. Backing that bullishness is its history, good margins, pipeline, capital allocation, and more
Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.
These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term.
On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aorti
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE